Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phenolphthalein safety data needed, FDA says at OTC "feedback" mtg..

This article was originally published in The Tan Sheet

Executive Summary

PHENOLPHTHALEIN HUMAN AND ANIMAL SAFETY DATA NEEDED, FDA said at a Dec. 18 OTC drug "feedback" meeting of FDA pharmacology and toxicology senior staff and OTC Products Division representatives, National Toxicology Program personnel and industry. FDA asked industry to conduct comparative studies of phenolphthalein in humans and animals after receiving results from animal studies by NTP that found evidence of carcinogenicity. FDA is trying to determine whether the animal tumorigenic data has relevance to humans.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel